🇨🇭·14h agoIndustry
Roche’s fenebrutinib significantly reduced relapses versus standard of care to approximately one every 17 years in RMS
Publisher
R
Roche Newsroom
Switzerland
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalIn-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on roche.com
Leave the platform to read the original full article on the publisher site.
Source: Roche Newsroom
Scope: Industry
Related coverage
More related coverage
Certara·2h ago
Certara Enters Definitive Agreement for the Sale of its Regulatory and Medical Writing Business to Veristat
Amneal Pharmaceuticals RSS·3h ago
Amneal Agrees to Acquire Kashiv BioSciences to Create Global Biosimilar Leader; Reports Strong Preliminary First Quarter 2026 Financial Results and Raises FY2026 Standalone Guidance
BioInformatics Online·6h ago
Update for LEGE
Chugai Pharmaceutical News·6h ago